Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Moxonidine Pill

Phase 1Small molecule

VVanderbilt University Medical Center

Moxonidine Pill is one of 2 small molecule programs targeting Postural Tachycardia Syndrome. It is currently in Phase 1.

1

Indications

1

Total Trials

1

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postural Tachycardia SyndromeActive, not recruiting

Postural Tachycardia SyndromePhase 1

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Postural Tachycardia Syndrome

#DrugCompanyPhaseTrials

Moxonidine

SSolvay Pharmaceuticals

Moxonidine Pill

VVanderbilt University Medical Center

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Unspecified1 trial

Autonomic Determinants of POTS - Pilot 2

Active, not recruiting·VVanderbilt University Medical Center·Phase 1·NCT04140721·48 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Moxonidine Pill. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Moxonidine Pill compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Moxonidine Pill. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vanderbilt University Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: VVanderbilt University Medical Center

Related News